Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
  • Aerobiology and pollution (2)
  • Allergen immunotherapy (8)
  • Allergy diagnosis (8)
  • Anaphylaxis (1)
  • Artificial Intelligence (1)
  • Asthma (1)
  • COVID19 (3)
  • Dermatology (1)
  • Epidemiology (1)
  • Food allergy (1)
  • Infections (2)
Poster available until
Poster categories
  • Thematic Poster Session (26)
keywords
Session Reference
  • L-TPS01 (11)
  • L-TPS02 (15)
  • L-TPS03 (14)
  • L-TPS04 (12)
  • L-TPS05 (13)
  • L-TPS06 (8)
  • L-TPS07 (11)
  • L-TPS08 (7)
  • L-TPS09 (13)
  • L-TPS10 (13)
  • L-TPS11 (12)
  • L-TPS12 (14)
  • L-TPS13 (13)
  • L-TPS14 (11)
  • L-TPS15 (7)
  • L-TPS16 (14)
  • L-TPS17 (13)
  • L-TPS18 (10)
  • L-TPS19 (10)
  • L-TPS20 (12)
  • L-TPS21 (12)
  • TPS01 (12)
  • TPS02 (8)
  • TPS03 (14)
  • TPS04 (9)
  • TPS05 (15)
  • TPS06 (11)
  • TPS07 (13)
  • x TPS08 (9)
  • TPS09 (9)
  • TPS10 (16)
  • TPS11 (13)
  • TPS12 (12)
  • TPS13 (11)
  • TPS14 (12)
  • TPS15 (15)
  • TPS16 (15)
  • TPS17 (12)
  • TPS18 (10)
  • TPS19 (7)
  • TPS20 (11)
  • x TPS21 (5)
  • TPS22 (3)
  • TPS23 (4)
  • TPS25 (12)
  • TPS26 (14)
  • TPS27 (12)
  • TPS28 (16)
  • TPS29 (16)
  • TPS30 (14)
  • TPS31 (15)
  • TPS32 (16)
  • TPS33 (14)
  • TPS34 (17)
  • TPS35 (15)
  • TPS36 (12)
  • TPS37 (15)
  • TPS38 (13)
  • TPS39 (14)
  • TPS40 (13)
  • TPS41 (9)
  • x TPS42 (12)
  • TPS43 (12)
  • TPS44 (14)
  • TPS45 (12)
  • TPS46 (8)
  • TPS47 (7)
  • TPS48 (5)
  • TPS49 (5)
  • TPS51 (12)
  • TPS52 (14)
  • TPS53 (8)
  • TPS54 (15)
  • TPS55 (13)
  • TPS56 (16)
  • TPS57 (12)
  • TPS58 (12)
  • TPS59 (13)
  • TPS60 (14)
  • TPS61 (11)
  • TPS62 (9)
  • TPS63 (10)
  • TPS64 (11)
  • TPS65 (8)
  • TPS66 (9)
  • TPS67 (9)
  • TPS68 (19)
  • TPS69 (8)
  • TPS70 (9)
  • TPS71 (11)
  • TPS72 (6)
  • TPS73 (5)
  • TPS75 (4)
26 results
Thumbnail

D1.136 - Allergen awareness of patients in allergology consultations at the pneumophthisiology department of the Ignace Deen University Hospital

Thumbnail

D1.134 - Mapping the Patient’s Journey Prior to Allergen Immunotherapy

Thumbnail

D1.135 - ”Bee Pollen” as a Potential Trigger for Anaphylaxis: A Case Study

Thumbnail

D1.137 - Characterization of Pana g 1, a novel allergen from Korean ginseng, Panax ginseng triggering Pollen-Food Allergy Syndrome

Thumbnail

D1.138 - IgE cross-reactivity between grass species in the presence of Japanese cedar pollen sensitization

Thumbnail

D1.139 - Staphylococcus aureus (carriage and sensitization) - is it a significant factor in allergic rhinitis?

Thumbnail

D1.144 - Global variations of IgE cross-reactivity in Cupressus allergy

Thumbnail

D1.145 - A Clinical Decision Support System (CDSS) based on Machine Learning for the diagnosis of Seasonal Allergenic Rhinitis (SAR) and patient-tailored AIT prescription

Thumbnail

D1.148 - Heterogeneity of sensitization profiles between Central and Southern European allergic patients

Thumbnail

D1.422 - A service review of the complex COVID-19 vaccination service

Thumbnail

D1.425 - Familial Cold Autoinflammatory Syndrome Post COVID-19 Vaccine: A Case Report

Thumbnail

D1.423 - Listening to Urticaria Patients Through Social Media: Analyzing the Impact of the COVID-19 Pandemic

Thumbnail

D1.424 - Clinical-epidemiological profile of patients with Post-Covid syndrome followed at a medical school outpatient clinic

Thumbnail

D1.426 - Cellular immunity profile in patients with urolithiasis in the presence of post-Covid syndrome

Thumbnail

D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria

Thumbnail

D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria

Thumbnail

D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117

Thumbnail

D2.354 - Questionnaire survey of new treatments for atopic dermatitis

Thumbnail

D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria

Thumbnail

D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria

Pagination

  • Current page 1
  • Page 2
  • Next page Next
  • Last page Last
Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2025 EAACI
Made with   by CYIM